期刊文献+

不同血液透析方案治疗终末期肾衰竭的效果比较 被引量:2

原文传递
导出
摘要 目的探讨不同血液透析方案治疗终末期肾衰竭的效果、毒素清除率及安全性。方法回顾性分析2015年12月—2017年12月收治的40例终末期肾衰竭患者,根据血液透析治疗方案的不同分为对照组和研究组,每组20例。两组患者均行常规饮食、药物治疗,同时对照组采取常规血液透析,研究组采取高通量血液透析,治疗3个月后对比两组患者相关毒素清除率、甲状旁腺激素(PTH)、血磷(P)、半胱氨酸蛋白酶抑制剂C (Cys-C)等血清水平值及感染率。结果研究组患者PTH、P、Cys-C等血清毒素清除率均显著高于对照组(P<0.05);治疗后,两组患者血清内皮素-1(ET-1)、血管紧张素Ⅱ(AngⅡ)、β2微球蛋白(β2-MG)水平值降低,一氧化氮(NO)水平值上升(P<0.05);且研究组患者ET-1、AngⅡ、β2-MG水平显著低于对照组,NO值显著高于对照组(P<0.05);研究组感染发生率10.00%显著低于对照组的30.00%(P<0.05)。结论相较于常规血液透析,对终末期肾衰竭患者采取高通量血液透析治疗能有效提高毒素清除率,改善血清指标,降低感染发生率。
出处 《慢性病学杂志》 2018年第11期1607-1608,1611,共3页 Chronic Pathematology Journal
  • 相关文献

参考文献7

二级参考文献81

  • 1Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States[J]. JAMA, 2007,298(17) : 2038-2047.
  • 2Voormolen N, Noordzij M, Gmotendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients [ J ]. Nephrol Dial Transplant, 2007, 22(10) :2909-2916.
  • 3Rebaca RG, Antonia GM, Beatriz GF, et al. FGF23 in Type 2 Diabetic Patients: Relationship With Bone Metabolism and Vascular Disease[J]. Diabetes Care, 2014, 37(5) :e89-e90.
  • 4Guti6rrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis [J]. N engl J Med, 2008, 359(6) :584-592.
  • 5Rika J, Tatsuo S. Cardiovascular Risk Factors and Chronic Kidney Disease - FGF23:A Key Molecule in the Cardiovascular Disease [ J]. Int J Hypertens, 2014,2014:381082.
  • 6Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum ereatinine: a ne,a prediction equation. Modification of Diet in Renal Disease Study Group[J]. Ann Intern Med, 1999, 130(6) :461-470.
  • 7KDIGO CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease - mineral and bone disorder (CKD- MBD) [ J]. Kidney Int Suppl, 2009, 76 ( Suppl 113) : S1-S130.
  • 8Rodrigo B, Ana LE, Fabiana G, et al. Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? [J]. Clin J Am Soc Nepbrol, 2010, 5(2) :286-291.
  • 9Srivaths PR, Goldstein SL, Krishnamurthy R, et al. High serum phosphorus and FGF 23 levels are associated with progression of coronary calcifications[ J ]. Pediatr Nephrol, 2014,29 ( 1 ) : 103- 109.
  • 10Arnlov J, Carlsson AC, Sundstrom J, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology [ J J. Clin J Am Soc Nephrol, 2013,8 (5) :781-786.

共引文献153

同被引文献13

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部